POSEIDON: Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
Observational
Phase not listed
Yongchang Zhang
Sponsor: Hunan Province Tumor Hospital
Last Updated: December 27, 2023 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.